At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Psilocybin + Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
In Brief
A Phase 2 clinical trial evaluating Psilocybin + Placebo and Psilocybin + Escitalopram for Depressive Disorder, Major. Completed, enrolled 59 participants across 1 site.
Detailed Summary
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor (SSRI) escitalopram for major depressive disorder (MDD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesUnited Kingdom
CollaboratorsAlexander Mosely Charitable Trust
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartJan 2019
Primary CompletionApr 2020
Study CompletionOct 2020
TodayJul 2026
First PostedFeb 12, 2018
Enrollment StartJan 7, 2019
Primary CompletionApr 17, 2020
Study CompletionOct 17, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.4 years ago
Interventions
Psilocybin + Placebodrug
Multiple dosing days psilocybin vs 6 weeks of daily placebo
Psilocybin + Escitalopramdrug
Multiple dosing days psilocybin vs 6 weeks of daily escitalopram